Paper Details

Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Faculty Members have conducted research related to the Effects of Celecoxib on Electroconvulsive Therapy-Induced Cognitive Impairment in Patients With Major Depressive Disorder: A Pilot, Double-Blind, Placebo-Controlled Trial

Abolghasem Yousefi

Abolghasem Yousefi

Assistant Professor of Anesthesiology

Department Anesthesiology

School of Medicine

Amir Alam Hospital

Tehran University of Medical Sciences

Related Documents

1. Effects of Celecoxib on Electroconvulsive Therapy-Induced Cognitive Impairment in Patients With Major Depressive Disorder: A Pilot, Double-Blind, Placebo-Controlled Trial, Acta Medica Iranica (2019)

All Documents

1. Effect of Vitamin B1 Supplementation on Blood Creatinine and Lactate Levels and Clinical Outcomes in Patients in Intensive Care Units: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrition Reviews (2024)

2. Evaluation of Depression, Anxiety and Stress Scores in Patients With Covid-19: A Cross-Sectional Study, Archives of Anesthesiology and Critical Care (2024)

3. A Comparison of Laryngospasm in No Touch and Head Down Deep Extubation: A Randomized Clinical Trials, Archives of Anesthesiology and Critical Care (2023)

4. Effects of Nandrolone on Outcomes and Metabolic Response in Critically Ill Patients, Archives of Anesthesiology and Critical Care (2023)

5. The Omega-3 and Nano-Curcumin Effects on Vascular Cell Adhesion Molecule (Vcam) in Episodic Migraine Patients: A Randomized Clinical Trial, BMC Research Notes (2021)

6. Effects of Celecoxib on Electroconvulsive Therapy-Induced Cognitive Impairment in Patients With Major Depressive Disorder: A Pilot, Double-Blind, Placebo-Controlled Trial, Acta Medica Iranica (2019)

7. The Neuromodulatory Effects of Ω-3 Fatty Acids and Nano-Curcumin on the Cox-2/ Inos Network in Migraines: A Clinical Trial Study From Gene Expression to Clinical Symptoms, Endocrine# Metabolic and Immune Disorders - Drug Targets (2019)